文献速递艾滋病与性传播感染

孕前已用抗逆转录病毒治疗的妊娠结局与孕期启动治疗比较

Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy.
PubMed 文献 · Clin Infect Dis · 2021-01-01

基于PROMISE 1077BF/1077FF随机试验,比较孕前已用抗逆转录病毒治疗(ART)与孕期确诊后重启ART的妇女后续妊娠结局。

要点

  • 孕前已用ART者低出生体重风险升高(RR 2.65,95%CI 1.20-5.81)。
  • 建议对孕前已用ART的孕妇加强产科和新生儿照护。

核心结论

  • 孕前已用ART的妇女后续妊娠不良结局风险增加。

研究设计与样本

  • PROMISE 1077BF/1077FF国际多中心随机试验的后续妊娠分析,共记录826位母亲939次后续妊娠。

主要发现

  • 意向性分析显示孕前已用ART者低出生体重(<2500g)风险升高(RR 2.65,95%CI 1.20-5.81)。

临床怎么用

  • 对孕前已用ART的孕妇应加强产科和新生儿照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Globally, the number of infected women of childbearing age living with human immunodeficiency virus (HIV) and conceiving on antiretroviral therapy (ART) is increasing. Evidence of ART safety at conception and during pregnancy and adverse pregnancy outcomes remains conflicting. The Promoting Maternal and Infant Survival Everywhere (PROMISE) 1077 breastfeeding (BF) and formula feeding (FF) international multisite trials provide an opportunity to examine the impact of ART at conception on pregnancy outcomes with subsequent pregnancies. METHODS: The PROMISE 1077BF/1077FF trials were designed to address key questions in the management of HIV-infected women who did not meet clinical guidelines for ART treatment during the time of the trials. After the period of risk of mother-to-child transmission was over, women were randomized to either continue or discontinue ART. We compared subsequent pregnancy outcomes of nonbreastfeeding women randomized to continue ART following delivery, or breastfeeding women randomized to continue ART following breastfeeding cessation who conceived while on ART to women randomized to discontinue ART, who restarted ART after pregnancy was diagnosed. RESULTS: Pregnancy outcomes of 939 subsequent pregnancies of 826 mothers were recorded. The intention-to-treat analyses showed increased incidence of low birth weight (<2500 g) for women who conceived while on ART (relative risk, 2.65 [95% confidence interval {CI}, 1.20-5.81]), and also a higher risk of spontaneous abortion, stillbirth, or neonatal death (hazard ratio, 1.40 [95% CI, .99-1.98]) compared to women who restarted ART after they were found to be pregnant during trial follow-up. CONCLUSIONS: We found an increased risk for adverse pregnancy outcomes in women conceiving on ART, emphasizing the need for improved obstetric and neonatal care for this group. CLINICAL TRIALS REGISTRATION: NCT01061151.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Theron G, Brummel S, Fairlie L, et al. Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy. Clin Infect Dis. 2021. PMID: 32564058. doi:10.1093/cid/ciaa805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。